Delving into the Latest Updates on SARS-CoV-2(ViroStatics) with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Virostatics Srl

Active Organization

Virostatics Srl

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Purpose: To determine the impact of SARS-CoV-2 infection and immunization on ovarian response to controlled ovarian stimulation (COS) and embryo development after in vitro fertilization (IVF) Methods: A retrospective multicentric cohort study of 427 oocyte donors was conducted between January 1st, 2018 and September 18th, 2022. Patients who recovered from SARS-CoV-2 infection, vaccinated or non-exposed were included. Demographic, cycle characteristics, and laboratory outcomes were compared.

Start Date12 Dec 2021

Sponsor / Collaborator

Novafem

100 Clinical Results associated with SARS-CoV-2(ViroStatics)

Login to view more data

100 Translational Medicine associated with SARS-CoV-2(ViroStatics)

Login to view more data

100 Patents (Medical) associated with SARS-CoV-2(ViroStatics)

Login to view more data

100 Deals associated with SARS-CoV-2(ViroStatics)

Login to view more data